Science writer and independent researcher specialising in natural compound pharmacology and translational oncology. Tracking EBC-46 (tigilanol tiglate) and Blushwood berry extract since 2019.
Human Trials
A look at where tigilanol tiglate human clinical trials have been conducted to date and what the geographic footprint tells us about EBC-46 translational research priorities.
Mechanism of Action
How tigilanol tiglate intersects with endoplasmic reticulum stress and the unfolded protein response — PERK, IRE1α and ATF6 — and what published evidence shows about the EBC-46 cell-death cascade.
Regulatory
How Mexico's COFEPRIS classifies herbal remedies (remedios herbolarios) and dietary supplements (suplementos alimenticios), and what this means for EBC-46 blushwood berry products.
Consumer Reports
What users report about how blushwood berry tincture stability changes after the first opening, and how headspace oxygen, light, and refrigeration interact during normal use.
Botany
How leaf-level water potential, stomatal regulation, and xylem hydraulics shape the cultivation envelope for Fontainea picrosperma, the blushwood berry tree behind EBC-46.
Human Trials
How ctDNA / liquid biopsy is emerging as a dynamic biomarker for monitoring early response, residual disease, and recurrence in tigilanol tiglate (EBC-46) clinical trials.
Mechanism of Action
How the cellular stress response system — including HSP70 and HSP90 chaperones — interacts with tigilanol tiglate (EBC-46) signalling, and what this means for tumour cell death cascades.
Regulatory
How China's NMPA classifies imported botanicals under the Health Food (Bao Jian Shi Pin) framework and what this means for EBC-46 supplements seeking market entry.
Consumer Reports / Supplement
What EBC-46 supplement users report about the carrier base of blushwood berry tinctures — ethanol vs. glycerin formulations, taste, extraction completeness, and storage trade-offs.
Natural Source / Botany
How temperature regimes shape the cultivation envelope for Fontainea picrosperma — the blushwood berry tree that produces EBC-46 (tigilanol tiglate) — and what controlled-environment growers need to know.
Human Trials
How clinical researchers structure combination trials pairing tigilanol tiglate with other oncology agents — design considerations, endpoints, and what published work has examined.
Mechanism of Action
How autophagy — the cell's recycling system — interacts with the tigilanol tiglate (EBC-46) signalling cascade, and what published research suggests about its role in tumour cell death.